In conclusion, our study revealed that MVA pathway activation indicates a poorer prognosis in BLCA patients, that FDPS, a key enzyme of the MVA pathway, is highly expressed in BLCA, and that its protein stability is regulated by the PSME3-mediated ubiquitin-independent proteasome system. Here, PSME3 is linked to bladder transitional cell carcinoma.